KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Research & Development (2016 - 2025)

Boston Scientific's Research & Development history spans 17 years, with the latest figure at $569.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 23.97% year-over-year to $569.0 million; the TTM value through Dec 2025 reached $2.1 billion, up 27.06%, while the annual FY2025 figure was $2.1 billion, 27.06% up from the prior year.
  • Research & Development for Q4 2025 was $569.0 million at Boston Scientific, up from $514.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $569.0 million in Q4 2025 and bottomed at $276.0 million in Q1 2021.
  • The 5-year median for Research & Development is $357.0 million (2023), against an average of $380.4 million.
  • The largest annual shift saw Research & Development fell 8.0% in 2021 before it skyrocketed 37.34% in 2025.
  • A 5-year view of Research & Development shows it stood at $320.0 million in 2021, then grew by 3.12% to $330.0 million in 2022, then increased by 10.0% to $363.0 million in 2023, then rose by 26.45% to $459.0 million in 2024, then rose by 23.97% to $569.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Research & Development are $569.0 million (Q4 2025), $514.0 million (Q3 2025), and $526.0 million (Q2 2025).